Opinion|Videos|January 16, 2026
The Role of Elacestrant in ER+/HER2– Advanced Breast Cancer Harboring ESR1 Mutations
Author(s)Hope S. Rugo, MD, FASCO, Seth Wander, MD, PhD
Experts discuss the integration of oral SERDs like elacestrant into clinical practice, highlighting their benefits for ESR1 mutant populations in breast cancer treatment.
Advertisement
Episodes in this series
Hope S. Rugo, MD, and Seth Wander, MD, PhD, explore the clinical role of elacestrant (Orserdu) in estrogen receptor/HER2-negative advanced breast cancer with ESR1 mutations following the agent’s January 2023 FDA approval for use in patients with disease progression following at least 1 line of endocrine therapy. They discuss how this oral SERD addresses endocrine resistance and fits into current treatment algorithms. Rugo and Wander place elacestrant’s activity in context of evolving post-CDK4/6 inhibitor therapeutic options.
Advertisement
Related to this article
Divesiran lowered phlebotomy needs, raised ferritin, and improved MPN-10 symptom scores in phlebotomy-dependent polycythemia vera.
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Advertisement
Advertisement
Trending on OncLive
1
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
2
Study Identifies RNA Surveillance Defect That Fuels Melanoma Through Endogenous Retroviral RNA
3
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5